Caixin
Caixin Global – Latest China News & Headlines

Home >

TRENDING
U.S. Tightens Export Controls to Cover Subsidiaries of Blacklisted Firms
DeepSeek Unveils New Model With Sparse Attention, Slashes API Costs
Tech Brief (Sept. 30): U.S. Widens Export Blacklist
LATEST
Tech Brief (Sept. 30): U.S. Widens Export Blacklist
U.S. Tightens Export Controls to Cover Subsidiaries of Blacklisted Firms
DeepSeek Unveils New Model With Sparse Attention, Slashes API Costs
Tech Brief (Sept. 29): Meituan’s Food-Delivery Platform Keeta Launches in Dubai
Chinese Chipmaker Moore Threads Gets Fast Track Approval to $1.1 Billion IPO
Chinese Drone Maker XAG Files for Hong Kong IPO After First Annual Profit
GPT Weekly: Nvidia to Invest $100 Billion in OpenAI
Tech Brief (Sept. 26): Trump Approves TikTok Deal
Xiaomi Ups the Stakes in Premium Market With iPhone-Style 17 Series
Yangtze Memory’s Parent Restructures to Pave Way for IPO Amid Sanctions Pressures
Tech Brief (Sept. 25): Alibaba Launches AI Models
Alibaba Bets Big on ‘AI + Cloud’ With New Models, Nvidia Deal
GlobalFoundries Boosts U.S. Investment, Adds China Fabs to Meet Auto Chip Demand
Tech Brief (Sept. 24): Mercedes-Benz, ByteDance Partner on In-Car AI
Tech Brief (Sept. 23): Nvidia Plans $100 Billion Investment in OpenAI for AI Data Centers
Tech Brief (Sept. 22): Trump Says Murdoch Family May Be Involved in TikTok Deal
GPT Weekly: CoreWeave Secures $6.3 Billion Nvidia Order
Huawei Unveils Three-Year AI Chip Roadmap as Nvidia Faces Setbacks in China
Tencent Cloud Shuns Price War in Intensifying AI Race
China’s Regulator Ramps Up Push to Curb Food Delivery Subsidy War

By Han Wei / Dec 27, 2018 06:47 AM / Business & Tech

Photo: VCG

Photo: VCG

A Chinese herbal drugmaker is under public scrutiny after an online article went viral accusing the company of misleading advertising of a cancer treatment that was linked to the death of a 4-year-old girl in 2015.

Tianjin-based Quanjian Nature Medicine Technology Development Co. Ltd. faced a public outcry after Dingxiangyuan, an online health information service, published an article Dec. 25 accusing the company of using false advertising to cheat consumers.

The article linked Quanjian to the death of a girl who suffered from cancer and missed the opportunity of cure by taking therapy provided by Quanjian. The drugmaker denied any wrongdoing and demanded an apology from Dingxiangyuan, which refused.

Quanjian described itself as China’s biggest direct seller of herbal-based medicine and health-care products. Public records showed that the company’s 2017 revenue totaled more than 1 billion yuan ($145 million) with net profit of 128 million yuan.

A Caixin search of health-care product registration records found that only 13 among more than 100 products sold by Quanjian have proper registration records. Quanjian declined to comment.

The controversy surrounding Quanjian prompted the state market regulator to issue a notice Wednesday tightening requirements on marketing activities of direct sellers of health-care products.

A previous version of this story misstated the company’s name as Quanjian Group. It is Quanjian Nature Medicine Technology Development Co. Ltd., the major unit of Quanjian Group.

Share this article
Open WeChat and scan the QR code